0	2	An	an	DT
3	13	allosteric	allosteric	JJ
14	18	drug	drug	NN
18	19	,	,	,
20	37	o,o’-bismyristoyl	o,o'-bismyristoyl	NN
38	46	thiamine	thiamine	NN
47	56	disulfide	disulfide	NN
56	57	,	,	,
58	68	suppresses	suppress	VBZ
69	74	HIV-1	HIV-1	NNP
75	86	replication	replication	NN
87	94	through	through	IN
95	105	prevention	prevention	NN
106	108	of	of	IN
109	116	nuclear	nuclear	JJ
117	130	translocation	translocation	NN
131	133	of	of	IN
134	138	both	both	CC
139	144	HIV-1	HIV-1	NNP
145	148	Tat	Tat	NNP
149	152	and	and	CC
153	161	NF-kappa	NF-kappa	NNP
162	164	B.	B.	NNP
166	169	The	the	DT
170	178	efficacy	efficacy	NN
179	181	of	of	IN
182	199	o,o’-bismyristoyl	o,o'-bismyristoyl	NN
200	208	thiamine	thiamine	NN
209	218	disulfide	disulfide	NN
219	220	(	(	(
220	223	BMT	BMT	NNP
223	224	)	)	)
225	228	was	be	VBD
229	237	examined	examine	VBN
238	240	in	in	IN
241	247	detail	detail	NN
248	255	against	against	IN
256	261	HIV-1	HIV-1	NNP
262	272	laboratory	laboratory	NN
273	281	isolates	isolate	NNS
282	283	(	(	(
283	292	HTLV-IIIB	HTLV-IIIB	NNP
292	293	,	,	,
294	298	JRFL	JRFL	NNP
298	299	,	,	,
300	303	and	and	CC
304	306	MN	MN	NNP
306	307	)	)	)
307	308	,	,	,
309	316	primary	primary	JJ
317	325	isolates	isolate	NNS
326	327	(	(	(
327	330	KMT	KMT	NNP
331	334	and	and	CC
335	338	KMO	KMO	NNP
338	339	)	)	)
339	340	,	,	,
341	344	and	and	CC
345	351	simian	simian	JJ
352	368	immunodeficiency	immunodeficiency	NN
369	374	virus	virus	NN
375	376	(	(	(
376	385	SIVmac251	SIVmac251	NNP
385	386	)	)	)
387	389	in	in	FW
390	395	vitro	vitro	FW
395	396	.	.	.

397	400	BMT	BMT	NNP
401	410	inhibited	inhibit	VBD
411	414	the	the	DT
415	426	replication	replication	NN
427	429	of	of	IN
430	435	HIV-1	HIV-1	NNP
436	438	in	in	IN
439	443	both	both	CC
444	454	laboratory	laboratory	NN
455	458	and	and	CC
459	466	primary	primary	JJ
467	475	isolates	isolate	NNS
476	478	in	in	FW
479	484	vitro	vitro	FW
484	485	.	.	.

486	488	In	in	IN
489	497	addition	addition	NN
497	498	,	,	,
499	502	BMT	bmt	NN
503	512	exhibited	exhibit	VBD
513	522	antiviral	antiviral	JJ
523	531	activity	activity	NN
532	539	against	against	IN
540	549	SIVmac251	SIVmac251	NNP
549	550	.	.	.

551	561	Minimizing	minimize	VBG
562	568	energy	energy	NN
569	576	studies	study	NNS
577	579	of	of	IN
580	583	BMT	BMT	NNP
584	593	structure	structure	NN
594	600	reveal	reveal	VBP
601	605	that	that	IN
606	607	a	a	DT
608	623	trans-disulfide	trans-disulfide	NN
624	626	of	of	IN
627	635	thiamine	thiamine	NN
636	637	(	(	(
637	641	holo	holo	NN
642	646	drug	drug	NN
646	647	)	)	)
648	657	disulfide	disulfide	NN
658	659	(	(	(
659	662	TDS	TDS	NNP
662	663	,	,	,
664	673	protodrug	protodrug	NN
673	674	)	)	)
675	677	is	be	VBZ
678	692	allosterically	allosterically	RB
693	702	transited	transit	VBN
703	705	to	to	TO
706	709	the	the	DT
710	718	reactive	reactive	JJ
719	726	twisted	twisted	JJ
727	736	disulfide	disulfide	NN
737	739	of	of	IN
740	743	BMT	BMT	NNP
744	745	(	(	(
745	749	allo	allo	NN
750	754	drug	drug	NN
754	755	)	)	)
756	758	by	by	IN
759	776	o,o’-bismyristoyl	o,o'-bismyristoyl	NN
777	791	esterification	esterification	NN
792	794	of	of	IN
795	798	TDS	TDS	NNP
798	799	.	.	.

800	803	BMT	BMT	NNP
804	812	inhibits	inhibit	VBZ
813	820	nuclear	nuclear	JJ
821	834	translocation	translocation	NN
835	837	of	of	IN
838	842	both	both	CC
843	848	HIV-1	HIV-1	NNP
849	863	transactivator	transactivator	NN
864	865	(	(	(
865	868	TAT	TAT	NNP
868	869	)	)	)
870	873	and	and	CC
874	877	the	the	DT
878	886	cellular	cellular	JJ
887	902	transcriptional	transcriptional	JJ
903	910	nuclear	nuclear	JJ
911	920	factor-KB	factor-kb	NN
921	922	(	(	(
922	930	NF-kappa	NF-kappa	NNP
931	932	B	B	NNP
932	933	)	)	)
933	934	,	,	,
935	944	resulting	result	VBG
945	947	in	in	IN
948	951	the	the	DT
952	963	suppression	suppression	NN
964	966	of	of	IN
967	972	HIV-1	HIV-1	NNP
973	984	replication	replication	NN
984	985	.	.	.